2,849 Shares in Abbott Laboratories (ABT) Purchased by WealthTrust Axiom LLC
WealthTrust Axiom LLC acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,849 shares of the healthcare product maker’s stock, valued at approximately $209,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in ABT. Morgan Stanley lifted its holdings in Abbott Laboratories by 33.1% during the 2nd quarter. Morgan Stanley now owns 21,218,276 shares of the healthcare product maker’s stock valued at $1,294,103,000 after buying an additional 5,274,307 shares in the last quarter. Charles Schwab Investment Advisory Inc. bought a new stake in Abbott Laboratories during the 2nd quarter valued at about $275,697,000. American Century Companies Inc. lifted its holdings in Abbott Laboratories by 417.9% during the 2nd quarter. American Century Companies Inc. now owns 5,586,119 shares of the healthcare product maker’s stock valued at $340,697,000 after buying an additional 4,507,553 shares in the last quarter. BlackRock Inc. lifted its holdings in Abbott Laboratories by 3.7% during the 2nd quarter. BlackRock Inc. now owns 116,149,740 shares of the healthcare product maker’s stock valued at $7,083,972,000 after buying an additional 4,153,157 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Abbott Laboratories by 12.0% during the 2nd quarter. Janus Henderson Group PLC now owns 13,708,172 shares of the healthcare product maker’s stock valued at $836,067,000 after buying an additional 1,468,430 shares in the last quarter. Institutional investors own 72.30% of the company’s stock.
Shares of Abbott Laboratories stock opened at $72.79 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.13 and a debt-to-equity ratio of 0.62. Abbott Laboratories has a 52-week low of $54.32 and a 52-week high of $74.15. The company has a market capitalization of $127.33 billion, a PE ratio of 25.80, a PEG ratio of 2.15 and a beta of 1.39.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 15th. Stockholders of record on Monday, October 15th will be given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.54%. The ex-dividend date is Friday, October 12th. Abbott Laboratories’s payout ratio is currently 44.80%.
In other news, insider Andrew H. Lane sold 9,097 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $67.11, for a total value of $610,499.67. Following the transaction, the insider now owns 35,576 shares of the company’s stock, valued at approximately $2,387,505.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Sharon J. Bracken sold 1,732 shares of Abbott Laboratories stock in a transaction that occurred on Friday, September 28th. The stock was sold at an average price of $73.35, for a total transaction of $127,042.20. Following the completion of the transaction, the senior vice president now directly owns 39,229 shares in the company, valued at approximately $2,877,447.15. The disclosure for this sale can be found here. In the last ninety days, insiders sold 203,297 shares of company stock worth $14,018,743. Insiders own 0.74% of the company’s stock.
Several equities research analysts have recently commented on ABT shares. Cowen boosted their price target on shares of Abbott Laboratories from $72.00 to $86.00 and gave the company an “average” rating in a report on Friday, October 5th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $77.00 price target for the company in a report on Tuesday, September 18th. Royal Bank of Canada restated a “buy” rating and issued a $70.00 price target on shares of Abbott Laboratories in a report on Thursday, July 19th. Stifel Nicolaus boosted their price target on shares of Abbott Laboratories from $71.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 19th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $80.00 price target on shares of Abbott Laboratories in a report on Thursday, October 18th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the stock. Abbott Laboratories has an average rating of “Buy” and a consensus target price of $75.22.
Abbott Laboratories Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.
Further Reading: Fundamental Analysis and Individual Investors
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.